Physician profile
Robert Chua
NPI 1245215375
$2,702.89
in general payments reported to CMS, 2019-2025
27 companies · $56.04 in 2025
The $56.04 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $561 · 2022: $931 · 2023: $1,078 · 2024: $76.25 · 2025: $56.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,115 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,115.38 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $383.36 | 2021-2023 | Wegovy, Ozempic, Rybelsus |
| Astellas Pharma US INC | $247.43 | 2021-2024 | Myrbetriq, Veozah |
| Lilly USA, LLC | $243.15 | 2021-2023 | Mounjaro, Trulicity |
| Pfizer INC. | $231.36 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $217.08 | 2021-2023 | |
| Amgen INC. | $191.25 | 2021-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $180.26 | 2021-2023 | Trelegy Ellipta |
| Abbvie INC. | $147.54 | 2021-2024 | Qulipta, Ubrelvy, Synthroid |
| Astrazeneca Pharmaceuticals LP | $124.93 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.08 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $82.99 | 2022-2023 | Belsomra |
| Biohaven Pharmaceutical Holding Company LTD. | $80.63 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.01 | 2021-2023 | Stiolto Respimat |
| Eisai INC. | $49.84 | 2021-2022 | |
| Dexcom, INC. | $49.61 | 2022-2023 | Dexcom G6 Transmitter |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $43.67 | 2021 | |
| Janssen Pharmaceuticals, INC | $39.71 | 2022 | |
| Exact Sciences Corporation | $37.47 | 2023 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $31.42 | 2021 | |
| Boston Scientific Corporation | $29.34 | 2023 | Watchman Access System |
| Idorsia Pharmaceuticals US INC | $28.91 | 2023 | Quviviq |
| Ibsa Pharma INC. | $23.61 | 2023 | Tirosint, Licart |
| Biohaven Pharmaceuticals, INC. | $19.56 | 2021 | |
| Jazz Pharmaceuticals INC. | $18.86 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.29 | 2023 | Xifaxan |
| Biodelivery Sciences International, INC. | $14.98 | 2021 | |
| Almatica Pharma LLC | $14.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Chua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.